Translational Analysis of Gait as a Primary Outcome Measure in Angelman Syndrome | $282,870

Dr. Duis used the ActiMyo device(s) in a clinical study to evaluate the tolerability and gait parameters in Angelman syndrome. This device was shown to be well  tolerated and associated with various unique gait parameters when compared to neurotypical age-matched controls.

X
X